Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence data in Türkiye is limited. We aimed to determine the nationwide prevalence of MASLD and advanced hepatic fibrosis risk in subjects with cardiometabolic risk factors (CMRF). Despite recent international consensus redefining fatty liver disease terminology, no nationwide MASLD study has been reported in Türkiye. Methods: This cross-sectional study included 14,371 adults with ≥1 CMRF from 44 centers across 31 cities. MASLD was diagnosed using liver ultrasonography plus cardiometabolic criteria. Advanced fibrosis risk was assessed by fibrosis-4 (FIB-4) score (≥1.3 for ≤65 years; ≥2.0 for >65 years). Logistic regression was used to identify independent predictors of high FIB-4. Results: A total of 61.4% of participants were women, the mean age was 51.3 ± 14.4 years, and the mean BMI was 31.4 ± 6.0 kg/m2. MASLD prevalence was 75.7% (n = 10,873), rising with the number of CMRFs (56.5% with one factor vs. 83.4% with all). The prevalence of high FIB-4 scores was 12.0% overall, being lower in MASLD patients than non-MASLD patients (11.2% vs. 14.4%, p < 0.001). FIB-4 scores decreased with increasing BMI (28.1% underweight vs. 8.7% class III obesity). Male sex, T2DM, and hypertension independently predicted high FIB-4 scores, while smoking, higher BMI, and MASLD were inversely associated. Conclusions: Three-quarters of Turkish adults with CMRF have MASLD. Standard FIB-4 thresholds may underestimate fibrosis risk in obese and smoking populations, underscoring the need for adjusted cut-offs or alternative tools. This study is the first to provide nationwide MASLD prevalence data in Türkiye.
Objective: Hepatic steatosis commonly coexists with cardiometabolic risk factors, yet circadian blood pressure patterns in adults with hepatic steatosis remain incompletely characterized. This study aimed to describe ambulatory blood pressure patterns in adults with ultrasonographically detected moderate-to-severe hepatic steatosis. Methods: This single-center prospective observational study enrolled adults with grade 2 or 3 hepatic steatosis on abdominal ultrasonography between August 2023 and August 2024. All participants underwent 24-h ambulatory blood pressure monitoring after enrollment. Patients were classified as dipper or non-dipper according to nocturnal blood pressure decline, and clinical, biochemical, ultrasonographic, and ambulatory parameters were compared. Results: Among 137 patients, 43 (31.4%) had a dipper pattern and 94 (68.6%) had a non-dipper pattern. Grade 2 and grade 3 steatosis were present in 125 (91.2%) and 12 (8.8%) patients, respectively. In the exploratory multivariable analysis, age, sex, antihypertensive treatment, and ultrasonographic steatosis grade were not independently associated with non-dipping status. Ambulatory hypertension thresholds were met more often in the non-dipper group [72 (76.6%) vs. 25 (58.1%), p = 0.027]. Nocturnal hypertension was more frequent in the non-dipper group [72 (76.6%) vs. 22 (51.2%), p = 0.003]. The non-dipper group had higher 24-h systolic blood pressure [134.0 (122.0–145.0) vs. 130.0 (118.5–136.0) mmHg, p = 0.027]. The median nocturnal systolic blood pressure decline in the overall cohort was 6.0% [2.6–11.3], whereas daytime systolic and diastolic blood pressure values were comparable between groups. Conclusions: Non-dipping blood pressure was frequent in adults with moderate-to-severe hepatic steatosis. Ambulatory blood pressure monitoring provides a descriptive assessment of nocturnal blood pressure patterns in this selected hepatic steatosis cohort.